NICE refuses the appeal for Alzheimer's drug treatments

NICE has today (Wednesday 11 October) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer's disease have not been upheld.

Test for Alzheimer's disease
Test for Alzheimer's disease

This final guidance from NICE will recommend to the NHS in November that donepezil, galantamine and rivastigmine should only be considered as options for treatment of people with moderate Alzheimer’s disease. Memantine is only recommended as part of clinical studies for people with moderate-severe to severe Alzheimer’s disease.

In 2001 NICE guidance recommended that the Alzheimer’s drugs should be used as a standard treatment. However, a further appraisal in 2005 resulted in NICE stating that the drugs should be restricted as the cost of treating these patients was not supported by the available evidence.

The pharmaceutical manufacturers were asked to present further evidence of the effectiveness of these treatments in patients with mild Alzheimer’s disease.

Andrew Dillon, NICE chief executive, said: ‘Alzheimer’s is a cruel and devastating illness and we realise that today’s announcement will be disappointing to people with Alzheimer’s disease and those who treat and care for them. But we have to be honest and say that based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough difference for us to recommend their use for treating all stages of Alzheimer’s disease.’

Pfizer and Eisai, manufacturers of donepezil, are reported to be considering a judicial review of the decision.


eMIMS links

Alzheimer's dementia

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...